Search results
Atemwege. Etwa 4 bis 5% der Erwachsenen und mehr als 10 % der Kinder in Deutschland 1 sind von Asthma betroffen, während die COPD (chronisch obstruktive Lungenerkrankung) in Deutschland bis 2030 2 voraussichtlich um 24 % zunehmen wird. Cipla ist auf dem Weg, die Behandlung dieser Atemwegserkrankungen durch unsere breite Palette an Medikamenten ...
Drug Safety Reporting in Australia. 1800-569-074. Phone: +91 821-6643551 (Except US and EU) Email : drugsafety@cipla.com. Office, HR and Operations enquiries.
Cipla Limited is a Public incorporated on 17 August 1935. It is classified as Non-government company and is registered at Registrar of Companies, ROC Mumbai. Its authorized share capital is Rs. 1,750,000,000 and its paid up capital is Rs. 1,614,789,936.
Cipla Ltd (Cipla) manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women's health.
Cipla Q3 results: Pharma company's net profit jumps 32% to Rs 1,056 crore. Read More Details. Cipla’s #BerokZindagi partners with digital content platform FilterCopy.
Cipla reports 32% rise in net profit. Cipla shares jump 7%, hit 52-week high on strong Q3 earnings. Strong US sales growth, sustained domestic momentum helps Cipla Q1 net profit beat estimates. Cipla Q3 results: Pharma company's net profit jumps 32% to Rs 1,056 crore.
Cipla Ltd ₹ 1,510 1.97% 05 Jul - close price Export to Excel. Follow cipla.com BSE: 500087 NSE: CIPLA ...
